COMET clinical trial.

The COMET (Comparative Effectiveness of Monitoring with Care vs Standard Care in Women with Early-Stage Breast Cancer) clinical trial is evaluating the safety and effectiveness of active monitoring compared with standard care for patients with early-stage breast cancer (hormone receptor 1-2 positive).

The study aims to look at differences in health outcomes, side effects and quality of life for patients who have undergone surgery, with or without radiotherapy. Rather than starting additional treatments straight away, the active monitoring approach involves carefully tracking the disease through regular check-ups and tests.

COMET seeks to provide evidence on whether active monitoring can be a safe and effective option, with the potential to avoid the side effects of radiotherapy, while achieving good clinical outcomes. The findings from this trial could transform the management and treatment of early-stage breast cancer.

The results of the study suggest that active monitoring may help avoid aggressive treatments in selected patients with carcinoma. However, long-term follow-up is important to validate these findings and assess their impact on oncological outcomes.